![]() | ![]() |
Formats:
|
||||||||||||||||||||||||||||
Copyright © 2007 Highlander et al; licensee BioMed Central Ltd. Subtle genetic changes enhance virulence of methicillin resistant and sensitive Staphylococcus aureus 1Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA 2Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, USA 3Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA 4Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA 5University of Houston-Downtown, Houston, TX, USA 6University of Houston, Houston, TX, USA Corresponding author.Sarah K Highlander: sarahh/at/bcm.edu; Kristina G Hultén: khulten/at/bcm.edu; Xiang Qin: xqin/at/bcm.edu; Huaiyang Jiang: hjiang1/at/bcm.edu; Shailaja Yerrapragada: yerrapra/at/bcm.edu; Edward O Mason, Jr: emason/at/bcm.edu; Yue Shang: shang/at/bcm.edu; Tiffany M Williams: tmwillia/at/bcm.edu; Régine M Fortunov: fortunov/at/bcm.edu; Yamei Liu: yamei.liu/at/mail.uh.edu; Okezie Igboeli: igboeli/at/bcm.edu; Joseph Petrosino: jpetrosi/at/bcm.edu; Madhan Tirumalai: tmad/at/nsm.uh.edu; Akif Uzman: uzmana/at/uhd.edu; George E Fox: fox/at/uh.edu; Ana Maria Cardenas: acardena/at/bcm.edu; Donna M Muzny: donnam/at/bcm.edu; Lisa Hemphill: hemphill/at/bcm.edu; Yan Ding: yding/at/bcm.edu; Shannon Dugan: sdugan/at/bcm.edu; Peter R Blyth: pblyth/at/bcm.edu; Christian J Buhay: cbuhay/at/bcm.edu; Huyen H Dinh: hdinh/at/bcm.edu; Alicia C Hawes: ahawes/at/bcm.edu; Michael Holder: mholder/at/bcm.edu; Christie L Kovar: ckovar/at/bcm.edu; Sandra L Lee: sllee/at/bcm.edu; Wen Liu: wliu/at/bcm.edu; Lynne V Nazareth: lynnen/at/bcm.edu; Qiaoyan Wang: qiaoyanw/at/bcm.edu; Jianling Zhou: zhou/at/bcm.edu; Sheldon L Kaplan: skaplan/at/bcm.edu; George M Weinstock: gwstock/at/bcm.edu Received June 14, 2007; Accepted November 6, 2007. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. This article has been cited by other articles in PMC.Abstract Background Community acquired (CA) methicillin-resistant Staphylococcus aureus (MRSA) increasingly causes disease worldwide. USA300 has emerged as the predominant clone causing superficial and invasive infections in children and adults in the USA. Epidemiological studies suggest that USA300 is more virulent than other CA-MRSA. The genetic determinants that render virulence and dominance to USA300 remain unclear. Results We sequenced the genomes of two pediatric USA300 isolates: one CA-MRSA and one CA-methicillin susceptible (MSSA), isolated at Texas Children's Hospital in Houston. DNA sequencing was performed by Sanger dideoxy whole genome shotgun (WGS) and 454 Life Sciences pyrosequencing strategies. The sequence of the USA300 MRSA strain was rigorously annotated. In USA300-MRSA 2658 chromosomal open reading frames were predicted and 3.1 and 27 kilobase (kb) plasmids were identified. USA300-MSSA contained a 20 kb plasmid with some homology to the 27 kb plasmid found in USA300-MRSA. Two regions found in US300-MRSA were absent in USA300-MSSA. One of these carried the arginine deiminase operon that appears to have been acquired from S. epidermidis. The USA300 sequence was aligned with other sequenced S. aureus genomes and regions unique to USA300 MRSA were identified. Conclusion USA300-MRSA is highly similar to other MRSA strains based on whole genome alignments and gene content, indicating that the differences in pathogenesis are due to subtle changes rather than to large-scale acquisition of virulence factor genes. The USA300 Houston isolate differs from another sequenced USA300 strain isolate, derived from a patient in San Francisco, in plasmid content and a number of sequence polymorphisms. Such differences will provide new insights into the evolution of pathogens. Background Community acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) infections are increasing worldwide [1,2]. Although the emergence is concurrent, genetically distinct clones have been reported from different continents [3-6]. In the United States, two clones, USA300 and USA400 have been associated with the majority of CA-MRSA infections [7]. However, USA300 is currently being reported as the predominant cause of both adult and pediatric CA-MRSA infections in many states [8-12]. At Texas Children's Hospital (TCH) in Houston, Texas, we have observed a continuous increase of CA-S. aureus infections, predominantly CA-MRSA, in a prospective surveillance study initiated in 2001 [13]. Skin and soft tissue infections (SSTI) represented 94%; 58% of SSTI patients were hospitalized. We have also reported an increased number and severity of invasive cases, e.g. complicated pneumonia, osteomyelitis, pyomyositis, myositis and severe sepsis syndrome associated with the predominance of clone USA300 [9,14-18]. Similar observations have been described at other institutions across the United States [19]. Recent reports suggest that USA300 is more virulent than other MRSA strains [15,20,21]. USA300 is genetically related to the nosocomial MRSA strain COL, which emerged in the 1960s in Europe following the introduction of methicillin. Both of these strains are likely descendents of a methicillin-susceptible ancestral strain [22,23]. Approximately 75% of the CA-S. aureus strains at TCH are MRSA; 95% of these are USA300. In contrast to the homogeneity of CA-MRSA, CA methicillin-susceptible S. aureus (MSSA) from the same population are more heterogeneous; USA300 represented approximately 25% of these strains between 2000–2002 [9]. We continue to note a greater absolute increase in the number of CA-MRSA isolates, being virtually all USA300-MR, compared with CA-MSSA among children evaluated at TCH (Figures (Figures11
At the time of this writing, the complete genomes of eleven MRSA and MSSA clinical strains, of both community and hospital origin, plus a bovine S. aureus strain have been deposited in the GenBank database. Recently, the genome sequence of a multi-resistant USA300-MR isolate (FPR3757) from an abscess of an HIV-positive intravenous drug user was reported [24]. We present the sequence of a USA300-MR isolate from an otherwise healthy pediatric patient (USA300-HOU) and compare it to the genomes of FPR3757 and a USA300-MS isolate from TCH. We postulate that comparison of the genomes of USA300-MR and USA300-MS will provide clues to the enhanced ability of USA300-HOU-MR to spread and cause infections among children compared to other S. aureus clones circulating in Houston. Results Features of the USA300-HOU-MR genome The USA300-HOU-MR genome is 2,872,915 bp in length and was annotated to encode 2658 proteins, 59 tRNAs (plus one pseudogene), 5 ribosomal RNA operons and 21 non-coding RNAs (Table 1). A circular representation of the sequenced genome is shown in Figure Figure3.3
Pathogenicity islands and prophages More than fifteen different pathogenicity islands have been identified in the sequenced S. aureus genomes [25,26]. SaPIs are mobile genetic elements that carry about half of the known S. aureus toxin or virulence factor genes, and while strains contain different combinations of the islands, no strain appears to carry more than one copy of each type [27]. USA300-HOU-MR contains six, SaPI5, SaPIm4, SaPI6Δ, vSaα, vSaβ, and vSaγ. These encode enterotoxins, extotoxins and serine proteases as well as leukotoxin, hemolysin, exfoliatin, and epidermin (Figure (Figure33
USA300-HOU-MR carries two complete prophage sequences, SLT-USA300 and βC-USA300. Prophage remnants also occur within pathogenicity island SaPI5. The SLT-USA300 sequence is 98% identical to the 46139 bp SLT sequence [28], excepting gaps greater than 500 bp. These gaps represent regions in USA300 encoding a helicase and virulence-associated protein E, two DNA polymerases, and two prophage regulatory proteins. The prophage carries the Panton-Valentine leukocidin genes lukS-PV and lukF-PV. By PHYLIP analysis, the SLT-USA300 sequence is most similar to the prophages in MW2 and clinical strain A980470 (phiSLT) [28] (Figure (Figure5a).5a SLT-A980470 and -PVL, the SLT-USA300 attachment site lies within a conserved hypothetical protein gene [28,29]. The second prophage, βC-USA300, is very similar to β-hemolysin-converting prophages identified in JH1, JH9, MRSA252, MSSA476, Mu50, MW2, N315, Newman, and NCTC8325 (Figure (Figure5b).5b
Plasmids Two plasmids were detected in USA300-HOU-MR (Figure (Figure6a6a
Comparison of USA300-HOU-MR and USA300-FPR3757 We identified 14 insertions/deletions (indels) of greater than four bp between USA300- FPR3757 and USA300-HOU-MR (Table 4). The most significant difference between the two strains is the location of a 13.4 kb insertion. In USA300-FPR3757, this region is inserted at nt 1,630,721 between a biotin carboxylase carrier protein gene, accB, and the elongation factor P gene efp. In USA300-HOU-MR, this same 13 kb segment of DNA is inserted at nt 680,375 within the snoA gene at the beginning of the staphylococcal nuo-like operon, which encodes an NADH dehydrogenase [31]. The 13 kb segment is also found in COL, at the same location as in USA300-FPR3757, and in MRSA252 between two bacteriophage protein genes. There is no homology flanking the insertions sites for this element and there are no obvious recombination sequences or repeats within the segment. The first gene in the segment encodes a frameshift of an ISSA1 transposase. The frameshift occurs in a poly adenine tract so sequence variation through slipped-strand mispairing is possible. Six of the proteins encoded by the 13 kb segment may be non-classically secreted proteins. Also encoded are a possible lipoprotein, a peptidoglycan hydrolase, a cell division protein, a GTP-binding protein, a replication protein and a possible actin-binding protein.
An insertion of 159 bp in USA300-HOU-MR but not in USA300-FPR3757 occurs within a staphylococcal conserved hypothetical protein between 1857878 and 1858036. This insertion is a duplication of flanking sequence and maintains the reading frame of the protein. Another difference identified is a 47 bp region in USA300-FPR3757, within the repeated region of the IgG binding protein gene; again, these are absent from USA300-HOU. Additional short deletions in USA300-HOU-MR also occur within intergenic regions. Also of note is a frameshift in the gene encoding an AraC family transcriptional regulator in USA300 (742860–745009). This frameshift is not observed in any of the other sequenced S. aureus strains. In addition, we identified a frameshift in the cell wall anchor protein gene (2623054–2626400) not reported in the annotation of FP3757. Comparison of the two USA300 sequences revealed 92 single nucleotide polymorphisms (SNPs) and two four bp. deletions (Additional file 2). We also discovered 53 sequencing errors in the FPR357 sequence. Fifty-five of the SNPs map within ORFs, while 18 map within intergenic regions (this is consistent with the fact that 80% of the genome is coding sequence) and 7 map within rRNA sequences. Twenty-one of the changes within reading frames are synonymous, 34 are non-synonymous and 7 caused frameshifts. Two of the SNPs may explain differences in antibiotic susceptibility. One, a T (FPR357) to C (HOU) change in the gyrA gene causes a leucine to serine change at amino acid 84. The serine-containing GyrA protein confers resistance to ciprofloxacin (FPR357), while leucine confers the wild-type, susceptible phenotype (HOU, Table 2) [32]. A second SNP presumed to be involved in fluoroquinolone resistance maps within the topoisomerase IV parC gene. Here, the USA300-HOU-MR amino acid 80 is the wild-type serine, while USA300-FPR3757 has a tyrosine that confers resistance [33]. Three non-synonymous SNPs occur within the IgG binding protein A. SNPs in intergenic regions could affect gene regulation: a four base deletion at 2,627,226 would place a SarA binding motif closer to the sarU promoter and could affect its transcription (Figure (Figure77
We compared the USA300 SNPs to all other sequenced S. aureus strains (Additional file 2). For 39 of the SNPs, the other strains had the USA300-HOU-MR allele, while in 34 the allele was identical to FPR3757. For the remaining SNPs, the other strains showed both alleles, with some being triallelic. Comparison of USA300-HOU-MR and of USA300-HOU-MS We generated a draft sequence of the methicillin susceptible strain, USA300-HOU-MS, using the 454 Life Sciences pyrosequencing technology [34]. This strain is susceptible to all the antibiotics tested except penicillin (Table 1). The sequences were assembled into 326 contigs with a total contig length of 2.8 Mb. We observed 32 SNPs between the HOU-MRSA and MSSA strains (Additional file 1). We also identified two regions of DNA that are found in USA300-HOU-MR but not in USA300-HOU-MS. In contrast, we observed only one region in the MS strain not present in the USA300-HOU-MR strain. This 733 bp contig had a short DNA match (44 bp, 100% identity) to several staphylococcal sequences and a partial protein match (50% length, 38% identity) to a transport accessory protein. The sequences missing from USA300-HOU-MS included the SCCmec and ACME regions (34173–88845, Additional file 2). A second region not found in USA300-HOU-MS (680132 to 694219) includes a large number of staphylococcal conserved hypothetical proteins (Additional file 2). Four of the proteins encoded by this region may be secreted (two non-classical). Also encoded are a possible lipoprotein, a peptidoglycan hydrolase, a cell division protein, ATP- and GTP-binding proteins, a replication protein, a possible secreted actin-binding protein, a possible ornithine carbamoyltransferase and a possible histidinol dehydrogenase. We surveyed other sequenced staphylococcal genomes using TBLASTX for the presence of ORFs that were homologous to proteins encoded by the regions of USA300-HOU-MR that were missing in the MSSA strain. These are shown in Additional file 2. With the exception of a few matches in the MW2 genome, the region from 51299 to 62735 seems to encode proteins unique to USA300-MR. This region also encodes four hypothetical and six conserved hypothetical proteins; several of these, although present, were not annotated in USA300-FPR3757. As previously discussed, this region may encode several secreted proteins. Though the arginine deiminase DNA region is unique to USA300 and to S. epidermidis ATCC 12228, genes encoding homologues of the proteins are found elsewhere in the USA300-HOU-MS genome and in most of the complete staphylococcal genomes. Proteins weakly similar (e value > e-10) to the nickel transporter were found in all staphylococcal genomes but this is likely due to generalized matches to other ABC transporter subunits. In contrast, the nickel transporter proteins are most homologous to proteins encoded by Staphylococcus haemolyticus. The proteins encoded by the region between 680132 and 694219 are also encoded by the genomes of two nosocomial MRSA strains, COL and MRSA252. These were not found in the CA isolate MW2. USA300-HOU-MS does not carry plasmid pUSA300-HOU-MR but it does carry a 21 kb plasmid (pUSA300-HOU-MS) that encodes resistance to beta-lactams and to cadmium (Figure (Figure6c).6c Comparison with other completely sequenced staphylococcal genomes We used Mauve [35] to align the sequences of the seventeen completed sequenced staphylococcal genomes (Figure (Figure8)8
Discussion Because of the rapid and continuing increase of the prevalence of CA USA300 strains at TCH, we initiated the sequencing of two typical isolates from pediatric patients. During this time, Diep et al. [24] reported the sequence of USA300-FPR3757. USA300-HOU-MR revealed significant differences from USA300-FPR3757. Though USA300-FPR3757 was chosen as a highly resistant isolate, USA300-HOU-MR, a purely community-acquired strain, harbours a large plasmid encoding multiple antibiotic and cadmium resistance. The mosaic composition of plasmid pUSA300-HOU-MR representing three different staphylococcal plasmids points toward significant genetic exchange between staphylococcal isolates and species. Among the numerous antibacterial resistance genes found on the plasmid, the conferred resistance to bacitracin, a common constituent of topical over-the-counter ointments used to treat or prevent cutaneous infections, is most intriguing. In contrast to other MR strains, the cadmium resistance genes were found on a plasmid and not on the chromosome. Genome-wide alignments revealed that not all MRSA are tightly clustered. Several indels between USA300-HOU-MR and USA300-FPR3757 were identified. The majority of the indels were within repeat regions or rRNAs, though a 13 kb segment was located in different regions of the two genomes. In USA300-FPR3757, the region is inserted between two genes. In USA300-HOU-MR, the segment interrupts an operon (snoABCDEFG) that has been implicated in susceptibility to thrombin-induced platelet microbicidal protein 1 (tPMP-1). Bayer et al. [31] have shown that interruption of this operon reduces the susceptibility of S. aureus to tPMP-1 in vitro. Resistance to tPMP-1 may allow US300-HOU-MR to cause more serious disease by evasion of platelet-mediated killing in the blood stream. USA300-FPR3757 has an additional repeat within the gene encoding the IgG binding protein A, so it is possible that IgG binding protein is subject to structural variation. We also identified nine SNPs within this gene. This may suggest that the IgG binding protein undergoes significant variation, possibly in response to the host. Two prophage were identified, one carrying the PVL genes and the other an hemolysin converting phage carrying the staphylokinase, chemotaxis inhibitory protein and staphylococcal complement inhibitor genes. USA300 lacks a copy of prophage L54a. The GehD lipase, whose gene contains the prophage attachment site, is likely to play a role in colonization events. [36]. SNP analysis revealed 47 non-synonymous, non-conserved differences between the strains. Some of these may affect protein function. Two of these, one in gyrA and one in parC, are consistent with antibiotic susceptibilities reported in Table 3. The SNP analysis also revealed a number of sequencing errors in the FPR3757 sequence. To further our understanding of the evolution of the USA300-HOU-MR strain, we created a draft sequence of an MS isolate from TCH. This revealed two regions of the MR strain not found in the MS strain. It is likely that the progenitor MS strain acquired these regions (along with the SCCmecIVa and the arginine deiminase region) by recombination to become USA300-HOU-MR. We propose that USA300-HOU-MS first acquired the arginine deiminase region plus the cassette chromosome recombinase genes (ccrAB) from a strain similar to S. epidermidis ATCC12228. This is based on the observation that the ccrAB genes in USA300-HOU-MR are 95–100% identical to those found near the arginine deiminase region in S. epidermidis ATCC12228. The SCCmec was likely acquired in a separate event from another MRSA, or from a MR-S. epidermidis strain, via ccrAB recombination within the repeats flanking the arginine deiminase region [24]. US300-HOU-MS lacks a probable nickel ABC transporter that is linked to ACME in USA300-MR. It is possible that increased intracellular stores of nickel in USA300-HOU-MR could contribute to virulence by enhancing the activity of the nickel-dependent urease. [37]. The MS strain also lacks a copy of the P-ATPase copper transporter gene; such transporters have been shown to be involved in virulence in Listeria monocytogenes [38]. Another potential virulence factor revealed by comparison of the MR and MS strains is a possible secreted actin binding protein. We used a relatively new predictive tool, SecretomeP2.0, to identify non-classically secreted proteins [39] since it is not possible to predict the function of most of these proteins by BLAST analysis. We found 406 high scoring genes predicted to encode non-classically secreted proteins in USA300-HOU-MR (Additional file 3). If some of these are indeed secreted then they may be candidate virulence factors for future study. Conclusion Comparative analyses have revealed that USA300-MRSA is highly similar to some MRSA strains suggesting that the differences in pathogenesis are due to subtle changes rather than to large-scale acquisition of virulence factor genes. Significantly, however, is the difference in plasmid content and antibiotic susceptibility profiles between the two USA300 isolates. The presence of a large multidrug resistance plasmid in a community-acquired isolate is unexpected. The combination of Sanger sequencing and 454 data allowed us to economically derive the complete sequence of USA300-HOU-MR and MS. Future sequencing of additional USA300 isolates will further characterize the genotypic variation in this clone. With exception of the antibiotic susceptibility profiles, the phenotypic results of the genotypic variation have yet to be discovered. Methods USA300 isolates Clinical isolate TCH1516 (USA300-HOU-MR) was obtained from an adolescent patient with severe sepsis syndrome [15]. The strain was representative of the predominant Sma I pulsed field gel electrophoresis (PFGE) pattern (Figure (Figure2)2 Antimicrobial susceptibilities DNA sequencing and genome assembly Genomic DNA was purified from CsCl gradients [42] and DNA sequencing was performed by Sanger dideoxy whole genome shotgun (WGS) and by the 454 Life Sciences pyrosequencing strategies [34]. Genomic and plasmid DNA from USA300-HOU-MR was sheared to a size of 2 kb by nebulization, and cloned into a derivative of pUC18 [43]. The clones were used for WGS DNA sequencing to 8× coverage by using dye terminator chemistry, data were collected on ABI 3730 sequencers, and reads were assembled using the ATLAS assembler [44]. This sequence was supplemented with contigs assembled from shorter reads generated on a 454 Life Sciences GS20 sequencer to 15× coverage. This combined assembly was refined by sequencing PCR products to fill in gaps and to resolve ambiguous regions. DNA from USA300-HOU-MS was sequenced by the 454 method to 17× coverage and the sequences assembled using the 454 Newbler assembler. The complete sequences have been deposited at DDBJ/EMBL/GenBank under the following the accession numbers: CP000730 (USA300-HOU-MR); CP000731 (pUSA300-HOU-MR); CP000732 (pUSA300-HOU-MS). The USA300-HOU-MS has been deposited under the project accession AASB00000000. The version described in this manuscript is the first version, AASB01000000. Glimmer [45] and GeneMark [46] were used independently to predict open reading frames (ORFs). Predicted proteins were compared to the nr database using BLASTP. Visualization of gene predictions was performed using the Genboree system [47] and the CONAN database [48]. Two individuals independently annotated each ORF and annotations were reconciled and converted to single entries within the database. Proteins lacking a homolog in the nr database were called hypothetical proteins, those with a homolog of no known function were called conserved hypothetical proteins and of these, if homologs were only in other staphylococci they were called staphylococcal conserved hypothetical proteins. Sequence analysis DNA comparisons were performed with BLASTN and BLASTZ. Protein sequences were analyzed by BLASTP and BLASTX and by the use of the predictive tools InterProScan [49], PFP [50], PSORTb [51], Helix-Turn-Helix Predictor [52], MEROPs [53], and the Tcdb Transport Classification database [54]. Non-classically secreted proteins (those lacking signal peptides) were predicted using SecretomeP2.0 [39]. Riboswitches and non-coding small RNAs were identified using BLASTN, the Riboswitch finder [55] and Riboswitch Explorer [56]. ClustalW [57] and Mauve [35] were used for multiple sequence alignments and PHLYIP bootstrapping and tree generation (evolution.genetics.washington.edu/phylip.html). Single nucleotide polymorphisms (SNPs) between USA300-MRSA-HOU and FPR3757 were verified by resequencing. Authors' contributions SKH performed much of the post-annotation analysis and wrote the draft of the manuscript. SKH, KGH, EOM, RMF, YL, OI, SY, JP, MT, AU, GEF annotated the genome. XQ and HJ contributed bioinformatics support. YS, TMW and AMC performed the SNP verification. DMM, LH, YD, SD, PRB, CJB, HHD, ACH, MH, CLK, SLL, WL, LVN, QW and JZ composed the sequencing and finishing team. KGH, RMF, EOM, SLK and GMW assisted critical review of the manuscript. All authors read and approved the final manuscript. Additional file 1 DNA regions present in USA300-HOU-MR but missing in USA300-HOU-MS and their presence in other sequenced staphylococcal genomes. Click here for file(361K, doc) Additional file 2 Single nucleotide polymorphisms and short insertions/deletions between USA300-MR, USA300-MS and FPR3757. Alleles in other sequenced S. aureus strains are also listed. Click here for file(508K, doc) Acknowledgements We thank Prisma Energy International and Vivian L. Smith Foundation for funding this project. We also would like to thank Magnus Hook, Gabriella Bowden, Berenice Carrillo, and Petra Matejkova for assistance during the early phases of the project. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||||||||
Clin Infect Dis. 2005 Feb 15; 40(4):562-73.
[Clin Infect Dis. 2005]Clin Microbiol Infect. 2006 Apr; 12 Suppl 2():3-10.
[Clin Microbiol Infect. 2006]J Clin Microbiol. 2004 Oct; 42(10):4735-43.
[J Clin Microbiol. 2004]Emerg Infect Dis. 2005 Jun; 11(6):973-6.
[Emerg Infect Dis. 2005]J Clin Microbiol. 2003 Nov; 41(11):5113-20.
[J Clin Microbiol. 2003]Pediatr Infect Dis J. 2005 Mar; 24(3):201-6.
[Pediatr Infect Dis J. 2005]Lancet. 2006 Mar 4; 367(9512):731-9.
[Lancet. 2006]J Bacteriol. 2005 Apr; 187(7):2426-38.
[J Bacteriol. 2005]Lancet. 2006 Mar 4; 367(9512):731-9.
[Lancet. 2006]J Bacteriol. 2005 Apr; 187(7):2426-38.
[J Bacteriol. 2005]Chem Immunol Allergy. 2007; 93():42-57.
[Chem Immunol Allergy. 2007]Trends Microbiol. 2004 Aug; 12(8):378-85.
[Trends Microbiol. 2004]Gene. 2001 May 2; 268(1-2):195-206.
[Gene. 2001]Gene. 1998 Jul 17; 215(1):57-67.
[Gene. 1998]J Bacteriol. 2006 Feb; 188(4):1310-5.
[J Bacteriol. 2006]J Bacteriol. 2006 Jan; 188(1):211-22.
[J Bacteriol. 2006]J Bacteriol. 1990 Dec; 172(12):7260-2.
[J Bacteriol. 1990]Antimicrob Agents Chemother. 1995 Jul; 39(7):1554-8.
[Antimicrob Agents Chemother. 1995]Nature. 2005 Sep 15; 437(7057):376-80.
[Nature. 2005]Genome Res. 2004 Jul; 14(7):1394-403.
[Genome Res. 2004]Lancet. 2006 Mar 4; 367(9512):731-9.
[Lancet. 2006]J Bacteriol. 2006 Jan; 188(1):211-22.
[J Bacteriol. 2006]J Biol Chem. 2002 Nov 8; 277(45):43017-23.
[J Biol Chem. 2002]Lancet. 2006 Mar 4; 367(9512):731-9.
[Lancet. 2006]FEMS Microbiol Lett. 1991 May 15; 64(2-3):277-81.
[FEMS Microbiol Lett. 1991]Microb Pathog. 1997 Feb; 22(2):67-78.
[Microb Pathog. 1997]BMC Microbiol. 2005 Oct 7; 5():58.
[BMC Microbiol. 2005]Pediatrics. 2005 Mar; 115(3):642-8.
[Pediatrics. 2005]Pediatr Infect Dis J. 2005 Mar; 24(3):201-6.
[Pediatr Infect Dis J. 2005]Lancet. 2006 Mar 4; 367(9512):731-9.
[Lancet. 2006]Nature. 2005 Sep 15; 437(7057):376-80.
[Nature. 2005]Anal Biochem. 1996 Apr 5; 236(1):107-13.
[Anal Biochem. 1996]Genome Res. 2004 Apr; 14(4):721-32.
[Genome Res. 2004]Nucleic Acids Res. 1999 Dec 1; 27(23):4636-41.
[Nucleic Acids Res. 1999]Nucleic Acids Res. 1998 Feb 15; 26(4):1107-15.
[Nucleic Acids Res. 1998]J Bacteriol. 2004 Sep; 186(17):5842-55.
[J Bacteriol. 2004]Bioinformatics. 2001 Sep; 17(9):847-8.
[Bioinformatics. 2001]Protein Sci. 2006 Jun; 15(6):1550-6.
[Protein Sci. 2006]Bioinformatics. 2005 Mar 1; 21(5):617-23.
[Bioinformatics. 2005]Protein Eng. 1988 Sep; 2(3):174-6.
[Protein Eng. 1988]Nucleic Acids Res. 2006 Jan 1; 34(Database issue):D270-2.
[Nucleic Acids Res. 2006]